Longeveron (LGVN) Change in Accured Expenses (2020 - 2026)
Longeveron's (LGVN) quarterly Change in Accured Expenses came in at $293000.0 in Q1 2026, up 270.35% year-on-year from $79114.6 in Q1 2025, and down 76.47% quarter-over-quarter from $1.2 million in Q4 2025.
Longeveron (LGVN) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Longeveron's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at $293000.0 for Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 270.35% year-over-year to $293000.0 in Q1 2026; TTM through Mar 2026 was $1.8 million, a 1228.21% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 388.68% from the prior year.
- Change in Accured Expenses fell to $293000.0 in Q1 2026 per LGVN's latest filing, from $1.2 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $1.2 million in Q4 2025 and bottomed at -$604000.0 in Q1 2022.
- The 5-year median for Change in Accured Expenses is $66000.0 (2024), against an average of $157529.4.
- Biggest YoY gain for Change in Accured Expenses was 1786.36% in 2025; the steepest drop was 375.76% in 2025.
- Year by year, Change in Accured Expenses stood at -$78000.0 in 2022, then jumped by 970.51% to $679000.0 in 2023, then slumped by 90.28% to $66000.0 in 2024, then jumped by 1786.36% to $1.2 million in 2025, then slumped by 76.47% to $293000.0 in 2026.
- Per Business Quant, the three latest LGVN Change in Accured Expenses figures stand at $293000.0 (Q1 2026), $1.2 million (Q4 2025), and -$182000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 | 293,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 293,000.00 |
| Mar 31, 2026 | 293,000.00 |
| Dec 31, 2025 | 1.25 Mn |
| Dec 31, 2025 | 1.25 Mn |
| Sep 30, 2025 | -182,000.00 |
| Sep 30, 2025 | -182,000.00 |
| Jun 30, 2025 | 404,000.00 |
| Jun 30, 2025 | 404,000.00 |
| Mar 31, 2025 | -172,000.00 |
| Mar 31, 2025 | -172,000.00 |
| Dec 31, 2024 | 66,000.00 |
| Dec 31, 2024 | 66,000.00 |
| Sep 30, 2024 | 66,000.00 |
| Sep 30, 2024 | 66,000.00 |
| Jun 30, 2024 | -116,000.00 |
| Jun 30, 2024 | -116,000.00 |
| Mar 31, 2024 | 249,000.00 |
| Mar 31, 2024 | 249,000.00 |
| Dec 31, 2023 | 679,000.00 |
| Dec 31, 2023 | 679,000.00 |